Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer

OncoImmunology

Volumn 6, Issue 1, 2017, Pages

  Huang, Ruea Yea ^a   Francois, Ariel ^a   McGray, Aj Robert ^a   Miliotto, Anthony ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antibody blockade; CTLA 4; Immune inhibitory checkpoint; LAG 3; Ovarian cancer; PD 1

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 2; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN ANTIBODY; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL CIRCUMFERENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; OVARY METASTASIS; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 85032006245     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1249561     Document Type: Article

References (45)

1. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102(51):18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
3. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12(6):492-9; PMID:21739672; http://dx.doi.org/10.1038/ni.2035
4. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012; 7(2):e30852; PMID:22347406; http://dx.doi.org/10.1371/journal.pone.0030852
5. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26(6):923-37; PMID:25465800; http://dx.doi.org/10.1016/j.ccell.2014.10.018
6. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA 2015; 112(21):6682-7; PMID:25964334; http://dx.doi.org/10.1073/pnas.1420370112
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26):2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
9. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37(5):473-84; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09.001
10. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439(7077):682-7; PMID:16382236; http://dx.doi.org/10.1038/nature04444
11. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33(3):225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb
12. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33(17):1974-82; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
13. De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, Tombolini V, Panici PB. Immunotherapy of ovarian cancer: the role of checkpoint inhibitors. J Immunol Res 2015; 2015:191832; PMID:26236750; http://dx.doi.org/10.1155/2015/191832
14. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25(2):208-24; PMID:25582080; http://dx.doi.org/10.1038/cr.2015.3
15. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S et al. Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33(34):4015-22; PMID:26351349; http://dx.doi.org/10.1200/JCO.2015.62.3397
16. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107(9):4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107
17. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72(4):917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
18. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73(12):3591-603; PMID:23633484; http://dx.doi.org/10.1158/0008-5472.CAN-12-4100
19. Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 2015; 6(29):27359-77; PMID:26318293; http://dx.doi.org/10.18632/oncotarget.4751
20. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2):122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
21. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207(10):2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
22. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999; 77(4):304-11; PMID:10457196; http://dx.doi.org/10.1046/j.1440-1711.1999.00835.x
23. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010; 116(8):1291-8; PMID:20472828; http://dx.doi.org/10.1182/blood-2010-01-265975
24. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107(17):7875-80; PMID:20385810; http://dx.doi.org/10.1073/pnas.1003345107
25. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27(4):670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006
26. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1(3):158-62; PMID:24777678; http://dx.doi.org/10.1158/2326-6066.CIR-13-0016
27. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9(3):162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
28. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181(8):5791-802; PMID:18832739; http://dx.doi.org/10.4049/jimmunol.181.8.5791
29. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116(10):2777-90; PMID:17016559; http://dx.doi.org/10.1172/JCI28828
30. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015; 37(4):764-82; PMID:25823918; http://dx.doi.org/10.1016/j.clinthera.2015.02.018
31. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73(23):6900-12; PMID:23975756; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550
32. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013; 8(12):e84927; PMID:24367702; http://dx.doi.org/10.1371/journal.pone.0084927
33. Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol 1994; 24(12):3216-21; PMID:7805750; http://dx.doi.org/10.1002/eji.1830241246
34. Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, Vignali DA. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009; 182(4):1885-91; PMID:19201841; http://dx.doi.org/10.4049/jimmunol.0800185
35. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8(5):765-72; PMID:8671665; http://dx.doi.org/10.1093/intimm/8.5.765
36. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10(1):29-37; PMID:19043418; http://dx.doi.org/10.1038/ni.1679
37. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 2015; 212(7):1125-37; PMID:26034050; http://dx.doi.org/10.1084/jem.20142237
38. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016; 7:10501; PMID:26883990; http://dx.doi.org/10.1038/ncomms10501
39. Bruniquel D, Borie N, Hannier S, Triebel F. Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics 1998; 48(2):116-24; PMID:9634475; http://dx.doi.org/10.1007/s002510050411
40. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11(12):852-63; PMID:22116087; http://dx.doi.org/10.1038/nri3108
41. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322(5899):271-5; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
42. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206(8):1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492
43. Martinez GJ, Pereira RM, Aijo T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, Zhang YC, Crotty S et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. Immunity 2015; 42(2):265-78; PMID:25680272; http://dx.doi.org/10.1016/j.immuni.2015.01.006
44. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21(4):585-91; PMID:10753190; http://dx.doi.org/10.1093/carcin/21.4.585
45. Woo SR, Li N, Bruno TC, Forbes K, Brown S, Workman C, Drake CG, Vignali DA. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol 2010; 40(6):1768-77; PMID:20391435; http://dx.doi.org/10.1002/eji.200939874